Gender differences in macroprolactinomas: Study of clinical features, outcome of patients and Ki-67 expression in tumor tissue

Frontiers of Hormone Research

Volumn 38, Issue , 2010, Pages 50-58

  Fainstein Day, Patricia ^a   Glerean, Mariela ^a   Lovazzano, Soledad ^a   Pietrani, Marcelo ^a   Christiansen, Silvia ^a   Balzaretti, Marta ^a   Kozak, Andrea ^a   Carrizo, Antonio ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CABERGOLINE; ESTRADIOL; KI 67 ANTIGEN; PROLACTIN; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; AGING; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CLINICAL FEATURE; ESTRADIOL BLOOD LEVEL; FEMALE; HEADACHE; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROSPECTIVE STUDY; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; VISUAL DISORDER;

ADULT; AGE FACTORS; ERGOLINES; ESTRADIOL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; SEX CHARACTERISTICS;

EID: 84926129209     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000318494     Document Type: Article

References (39)

1. Schlechte JA: Long-term management of prolacti-nomas. J Clin Endocrinol Metab 2007;92:2861-2865.
2. Melmed S: Update in pituitary disease. J Clin Endocrinol Metab 2008;93:331-338.
3. Verhelst J, Abs R: Hyperprolactinemia: pathophysi-ology and management. Treat Endocrinol 2003;2: 23-32.
4. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinhho LG, Wass JA, Giustina A: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-273.
5. Schlechte JA: Prolactinoma. N Eng J Med 2003;349: 2035-2041.
6. Schlechte JA, Dolan K, Sherman B, Luciano A: The natural history of untreated hyperprolactinemia. J Clin Endocrinol Metab 1989;2035-2041.
7. Walsh Jo, Pullan PT: Hyperprolactinaemia in males: a heterogeneous disorder. Aust NZ J Med 1980;13:241-247.
8. Pinzone JJ, Katznelson I, Danila DC, Pauler DK, Miller CS, Klibanski A: A primary medical therapy for micro-and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053-3057.
9. Colao A, Di Sarno A, Cappablanca P, Briganti F, Pivonello R, Di Somma C, Faggiano A, Biondi B, Lombardi G: Gender differences in the prevalence, clinical features and response to cabergoline in hyper-prolactinemia. Eur J Endocrinol 2003;148:325-331.
10. Danila DC, Klibansli A: Prolactin secreting pituitary tumors in men. Endocrinologist 2001;11:105-111.
11. Berezin M, Shimon I, Hadani M: Prolactinoma in 53 men: Clinical characteristics and models of treatment (male prolactinoma). J Endocrinol Invest 1995;18:436-441.
12. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J: Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 2000;85:3053-3057.
13. Trouillas J, Delgrange E, Jouanneau E, Maiter D, Guigard M P, Donckier J, Perrin G, Jan M, Tourniaire J: Prolactinoma in man: clinical and histological characteristics. Ann Endocrinol 2000;61:253-257.
14. Calle-Rrodriguez R, Giannini C, Scheithauer B, Lloyd R: Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 1998;73:1046-1052.
15. Newton CJ: Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells. J Steroid Biochem Mol Biol 1995;55: 327-336.
16. Haug E, Gautvik KM: Effects of sex steroids on pro-lactin secreting rat pituitary cells in culture. Endocrinology 1976;99:1482-1489.
17. Ishida M, Takahashi W, Itoh S, Shimodaira S, Maeda S, Arita J: Estrogen actions on lactotroph proliferation are independent of a paracrine interaction with other pituitary cell types: a study using lactotroph-enriched cells. Endocrinology 2007;148:3131-3139.
18. Hentges S, Sarkar DK: Transforming growth factor-beta regulation of estradiol-induced prolactinomas. Front Neuroendocrinol 2001;22:340-615.
19. Gillam M P, Middler S, Freed DJ, Molitch ME: The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002;87:4447-4451.
20. Cicarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G: PRL Secreting adenomas in male patients. Pituitary 2005;8:39-42.
21. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G: Outcome of cabergoline treatment in men with pro-lactinoma: effects of a 24-month treatment on pro-lactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004;89:1704-1711.
22. Leonard M P, NickelCJ, Marales A: Hyperprolactinemia and importance: why, when and how to investigate. J Urol 1989;142:992-994.
23. Kadioglu P, Oral G, Sayitoglu M, Erensoy N, Senel B, Gaziogllu N, Sav A, Cetin G, Ozbek U: Arometase cytochrome P450 enzyme expression in human pituitary. Pituitary 2008;11:29-35.
24. Nolan LA, Levy A: The effects of testosterone and oestrogen on gonadectomised and intact male rat anterior pituitary mitotic and apoptoctic activity. J Endocrinol Invest 2006;188:387-389.
25. Carretero J, Burks DJ, Vázquez G, Rubio M, Hernández E, Bodego P, Vázquez R: Expression of aromatase P450 is increased in spontaneous prolac-tinomas of aged rats 3. Pituitary 2002;5:5-10.
26. Thapar K, Yamada Y, Scheithauer B, Kovacs K, Yamada S, Stefaneanu L: Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol 1996;7:215-221.
27. Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, Horvath E, Kovacs K, Kuroki T, Young WF Jr, Sebo TJ, Riehle DL, Belzberg AJ: Corticotroph carcinoma of the pituitary: a clini-copathological study. Report of four cases. J Neurosurg 2002;96:352-360.
28. Crusius PS, Forcelini CM, Mallmann A, Silveira DA, Lersch E, Seibert C, Crusius M, Carazzo Ch, Crusius CU, Goellner E: Metastatic prolactinoma: case report with immunohistochemical asseessment for p53 and Ki-67 antigens. Arq. Neuro-Psiquiatr. 2005;63:864-869.
29. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-107.
30. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Févre-Montange M, Rey C, Figarella-Branger D, Raverot G, Melin MF, Lachuer J, Trouillas J: A diagnostic marker set for invasion, proliferation, and aggressiveness of pro-lactin pituitary tumor. Endoc Relat Cancer 2008;14: 987-990.
31. Verhelst J, Abs R, Maiter D,Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler Ch, Stevenaert A, Verlooy J, Beckers A: Cabergoline in the treatment of hyper-prolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
32. Molitch ME: Pharmacologic resistance in prolacti-noma patients. Pituitary 2005;8:43-52.
33. Gürlek A, Karavitaki N, Ansorge O, Wass,JA: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endo-crinol 2007;156:143-153.
34. Corsello SM, Ubertini M, Altomare RM, Lovicu MG, Rota CA, Colosimo C: Clinical giant prolacti-nomas in men: efficacy of cabergoline treatment. Endocrinology 2003;58:662-670.
35. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G: Drug insight: cabergoline and bro-mocriptine in the treatment of hyperprolactinemia in men and women. Nat Pract Endocrinol Metab 2006;2:200-204
36. Beverly MK, Molitch M, Vance L, Cannistraro K, Davis K, Simons JA, Schoenfelder JR, Klibansky A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergo-line. J Clin Endocrinol Metab 1996;81:2338-2343.
37. Biller BM: Medical therapy for prolactinomas and somatotroph adenomas. Endocr Pract 1996;2:333-337.
38. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G: Prolactinomas resistent to standard dopamine agonist respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-883.
39. Ferrari CI, Abs R, Bevan JS, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997:46:409-413.